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ABSTRACT  
Strategies to treat cachexia are still at its infancy. Enhanced muscle protein breakdown and ubiquitin-
proteasome system are common features of cachexia associated with chronic conditions including 
lung cancer (LC). Poly(ADP-ribose) polymerases (PARP), which play a major role in chromatin 
structure regulation, also underlie maintenance of muscle metabolism and body composition. We 
hypothesized that protein catabolism, proteolytic markers, muscle fiber phenotype, and muscle 
anabolism may improve in respiratory and limb muscles of LC-cachectic Parp-1-deficient (Parp-1
-/-
) 
and Parp-2
-/-
 mice. In diaphragm and gastrocnemius of LC (LP07 adenocarcinoma) bearing mice 
(wild type,  Parp-1
-/-
 and Parp-2
-/-
), PARP activity (ADP-ribose polymers, pADPr), redox balance, 
muscle fiber phenotype, apoptotic nuclei, tyrosine release, protein ubiquitination, muscle-specific E3 
ligases, NFkB signaling pathway, markers of muscle anabolism (Akt, mTOR, p70S6K, and 
mitochondrial DNA) were evaluated along with body and muscle weights and limb muscle force. 
Compared to wild type cachectic animals, in both respiratory and limb muscles of Parp-1
-/-
 and Parp-
2
-/-
 cachectic mice: cancer induced-muscle wasting characterized by increased PARP activity, protein 
oxidation, tyrosine release, and ubiquitin-proteasome system (total protein ubiquitination, atrogin-1, 
and 20S proteasome C8 subunit) were blunted, the reduction in contractile myosin and atrophy of the 
fibers was attenuated, while no effects were seen in other structural features (inflammatory cells, 
internal or apoptotic nuclei), and markers of muscle anabolism partly improved. Activation of either 
PARP-1 or -2 is likely to play a role in muscle protein catabolism via oxidative stress, NF-kB 
signaling, and enhanced proteasomal degradation in cancer-induced cachexia. Therapeutic potential 
of PARP activity inhibition deserves attention.  
Word count: 250 
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Introduction 
In advanced stages of respiratory and cardiac diseases and malignancies, the prevalence of muscle 
wasting and cachexia is very high (von and Anker, 2010;Diaz et al, 2014;Evans et al, 2008;Fearon et 
al, 2011;Leiro-Fernandez et al, 2014;Sanchez-Salcedo et al, 2015;Sanchez, 2015;Muscaritoli et al, 
2006). Muscle mass loss and dysfunction have a great impact on the patients’ quality of life as they 
severely compromise their exercise tolerance and daily-life activities. Additionally, muscle wasting 
and weakness were also shown to negatively influence disease prognosis and survival (Alvarez et al, 
2016;Barreiro, 2017;Evans et al, 2008;Fearon et al, 2011;Muscaritoli et al, 2006;Penalver Cuesta et 
al, 2015;Sanchez, 2015;Sebio et al, 2015;von and Anker, 2010). 
Despite that growing evidence has shown that mechanisms such as oxidative stress, systemic 
inflammation, ubiquitin-proteasome system, epigenetic modifications, metabolic derangements 
(Chacon-Cabrera et al, 2014;Fermoselle et al, 2011;Fermoselle et al, 2012;Puig-Vilanova et al, 
2014;Fermoselle et al, 2013;Chacon-Cabrera et al, 2015), and myostatin (Fermoselle et al, 
2011;Whittemore et al, 2003;Zhou et al, 2010) are involved in muscle wasting and cachexia, the 
contribution of other pathways that could have potential therapeutic implications remain to be fully 
identified. In this regard, it has been recently demonstrated (Chacon-Cabrera et al, 2014;Fermoselle 
et al, 2013;Chacon-Cabrera et al, 2015) that attenuation of mitogen-activated protein kinases 
(MAPK) and nuclear factor (NF)-κB signaling pathways induced beneficial effects on body and 
muscle weight loss and mitochondrial function in cancer-induced cachectic mice through the action 
of a cascade of molecular events.  
Poly(adenosine diphosphate-ribose) polymerases (PARPs) consist of  a family of proteins 
that catalytically cleave β-nicotinamide adenine dinucleotide (β-NAD
+
) into nicotinamide and ADP-
ribose and transfer the ADP-ribose moiety to acceptor residues of target proteins (Yelamos et al, 
2011). PARPs are involved in different biological functions such as maintaining genomic integrity, 
transcription, angiogenesis, cell death in oxidative stress-related pathologies, and metabolic and 
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immune regulation (Burkle and Virag, 2013;Yelamos et al, 2011). Overactivation of PARP, which 
may occur as a result of increased oxidant production, exerts deleterious effects on tissues mainly by 
depletion of intracellular NAD+ and ATP stores that lead to cell dysfunction and death (Ha and 
Snyder, 1999). Importantly, this mechanism of cell destruction participates in the etiology of 
conditions characterized by severe muscle wasting, such as acute lung and renal injuries (Kiefmann 
et al, 2004;Vaschetto et al, 2008;Zheng et al, 2005) and sepsis (Jagtap et al, 2002). On the other 
hand, PARP-1 and PARP-2 inhibition was also shown to promote oxidative metabolism and 
increased energy expenditure in skeletal muscles in other studies (Bai et al, 2011b;Bai et al, 2011a) 
and to attenuate muscle mass loss in cancer cachectic mice through epigenetic regulation (Chacon-
Cabrera et al, 2015). Whether inhibition of either PARP-1 or PARP-2 activities may mitigate muscle 
mass loss through attenuation of proteolysis and its upstream signaling pathways in models of 
cancer-induced cachexia remains to be fully understood. Elucidation of the biological mechanisms 
whereby PARP activity inhibition attenuates muscle mass loss may have potential therapeutic 
implications in the management of patients with cachexia as pharmacological inhibitors are currently 
available for the treatment of cancer.  
On this basis, we hypothesized that specific genetic deletion of Parp-1 and -2 in mice 
bearing a lung adenocarcinoma may mitigate increased muscle oxidative stress, protein breakdown 
and expression of proteolytic pathways, along with an improvement in the loss of contractile proteins 
and atrophy, and in anabolic markers. Moreover, as most of the studies conducted so far have 
focused on the assessment of the peripheral muscles, especially in patients, the analysis of the 
diaphragm muscle, which must remain continuously active, has also been included in the current 
investigation in order to compare potential differences in the target markers between these two 
muscles. This approach enabled us to analyze whether the activity of the muscle may influence the 
effects of PARP in cancer cachectic muscles.  
Accordingly, the following objectives were established to be analyzed in the diaphragm and 
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gastrocnemius muscles of Parp-1
-/-
 and Parp-2
-/-
 mice exposed to lung cancer (LC) cachexia for one 
month: 1) to explore levels of redox balance, protein degradation, markers of ubiquitin-proteasome 
pathway, contractile proteins, and muscle anabolism  including mitochondrial content and 2) to 
evaluate muscle structural abnormalities and phenotype, and the rate of apoptotic nuclei. Finally, in 
order to characterize and validate the reproducibility of the model of LC-induced cachexia as 
compared to previously published studies, body and muscle weights, muscle structure and limb 
muscle strength were also measured again in all the mice used for the purpose of the current 
investigation. In order to ensure PARP activity inhibition, its levels were also quantified in the target 
muscles of all the study animals.  
 
Materials and Methods  
(See additional information on all the methodologies in the online supplementary material). 
Animal model 
Tumor. LP07 is a cell line derived from the transplantable P07 lung tumor that appeared 
spontaneously in the lung of a BALB/c mouse (Diament et al, 1998). One month after cellular 
inoculation, all animals developed lung metastasis, spleen enlargement, and severe cachexia without 
affecting any other organs (Chacon-Cabrera et al, 2014;Chacon-Cabrera et al, 2015).  
Mice. BALB/c female mice (ten weeks old) were obtained from Harlan Interfauna Ibérica SL 
(Barcelona, Spain). Parp-1
-/-
 and Parp-2
-/-
 female mice (strain 129/Sv x C57BL/6), kindly provided 
by Dr. de Murcia (de Murcia et al, 1997) (Strasbourg, France), were backcrossed on BALB/c 
background for twelve generations. Genotyping was performed by PCR analysis using tail DNA as 
previously described (Corral et al, 2005). Following the principal of the 3Rs (replacement, reduction 
and refine) in order to reduce the number of mice used as much as possible, Parp-1
-/-
 and Parp-2
-/-
 
knockout animals were also used in another study with the aim to explore epigenetic regulation of 
muscle wasting (Chacon-Cabrera et al, 2015). 
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Experimental design and Ethics. In all experimental groups (except for control rodents), LP07 viable 
cells (4x10
5
) resuspended in 0.2 mL minimal essential media (MEM) were subcutaneously 
inoculated in the left flank of female BALB/c mice on day 1 and were studied for a period of one 
month. Fifty-eight mice were used in the study, which were further subdivided into the following 
groups: 1) control wild type (N=12), inoculation of 0.2 mL MEM; 2) LC-cachexia wild type group 
(N=14), inoculation of LP07 cells in 0.2 mL MEM; 3) control Parp-1
-/-
 (N=8), inoculation of 0.2 mL 
MEM; 4) LC-cachectic Parp-1
-/-
 mice (N=12), inoculation of LP07 cells in 0.2 mL MEM; 5) control 
Parp-2
-/-
 (N=6), inoculation of 0.2 mL MEM; and 6) LC-cachectic Parp-2
-/-
 mice (N=6), inoculation 
of LP07 cells in 0.2 mL MEM. This controlled study was designed in accordance with the ethical 
standards on animal experimentation (EU 2010/63 CEE, Real Decreto 53/2013 BOE 34, Spain) at 
PRBB and the Helsinki convention for the use and care of animals. Ethical approval was obtained by 
the Animal Research Committee (Animal welfare department, Catalonia, EBP-09-1228). 
In vivo measurements in the mice 
In all the study animals, body weight and food intake were measured every day during the entire 
duration of the study. The function of the peripheral muscles was also measured in vivo in all the 
study animals. Specifically, limb force was determined using a specific grip strength meter for 
rodents on days 0 and 30 in all animals as previously shown in published studies (Barreiro et al, 
2010a;Barreiro et al, 2016;Carter et al, 2004;Chacon-Cabrera et al, 2014;Chacon-Cabrera et al, 
2015;Fermoselle et al, 2013;Xu et al, 2008) and video-clips (Chacon-Cabrera et al, 2016b;Chacon-
Cabrera et al, 2016a). In all mice, the four limbs equally contributed to the maneuver of grip strength 
(Fig. E1). Control animals were paired-fed according to the amount of food eaten by the cancer 
cachectic rodents (3g/24h). Body weight and grip strength gain variables were calculated as the 
percentage of the measurements performed at the end of the study period (30 days) with respect to 
the same measurements obtained at baseline (day 0). In all the animals, body weight and limb 
strength gains were calculated as follows: (final body weight on day 30 – initial body weight on day 
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0)/ initial body weight on day 0 x 100, and (grip strength on day 30–grip strength on day 0)/ grip 
strength on day 0 x 100), respectively. 
Sacrifice and sample collection 
Mice from all experimental groups were always sacrificed on day 30 post-inoculation of LP07 cells 
or MEM (control animals), and diaphragm and gastrocnemius muscles (right hindlimb) were 
subsequently obtained. In all mice, the weight of each muscle was determined using a high-precision 
scale immediately after having been excised from the animals. LC-cachectic mice were 
macroscopically of smaller size than healthy control rodents (Chacon-Cabrera et al, 2014;Chacon-
Cabrera et al, 2015). Frozen tissues were used for immunoblotting and real-time polymerase chain 
reaction assay (qRT-PCR) techniques, while paraffin-embedded tissues were used for the assessment 
of muscle structure abnormalities and fiber type morphometry. 
Biological analyses 
PARP activity. In the current study, ADP-ribose polymers (pADPr) levels were identified in the 
muscle nuclei of both diaphragm and gastrocnemius as a marker of PARP enzyme activity following 
previous methodologies (Figs. E2A and E2B) (Lai et al, 2011). 
Muscle DNA isolation. Total DNA, including mitochondrial and nuclear DNA,  was isolated from 
diaphragm and gastrocnemius muscles of all mouse experimental groups using QIAmp DNA Mini 
Kit (QiAgen, GmbH, Germany) (Andreu et al, 2009), following the manufacturer’s protocol of DNA 
purification from tissues, and without the use of RNase A. Total DNA concentrations obtained from 
muscles were quantified using a spectrophotometer (NanoDrop, Thermo Scientific, Wilmington, 
Delaware, USA).   
Absolute quantification of DNAs. Mitochondrial DNA (mtDNA) copy number was estimated through 
the quantification of the mtDNA to nuclear DNA (nDNA) ratio (mtDNA/nDNA) by real-time PCR 
(Andreu et al, 2009;McDermott-Roe et al, 2011).  
Immunoblotting of 1D electrophoresis. Protein levels of the different molecular markers analyzed in 
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the study were explored by means of immunoblotting procedures as previously described (Chacon-
Cabrera et al, 2014;Salazar-Degracia et al, 2016). Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) was used as the loading control for all the immunoblots as shown in the corresponding 
figures. 
Protein catabolism. Protein degradation was explored on the basis of the rate of production of free 
tyrosine from muscle proteins as previously described (Chacon-Cabrera et al, 2014).  
Muscle fiber counts and morphometry. On 3-micrometer muscle paraffin-embedded sections from 
diaphragms and gastrocnemius muscles of all study groups, MyHC-I and –II isoforms were 
identified using specific antibodies (Chacon-Cabrera et al, 2014).  
Muscle structure abnormalities. The area fraction of normal and abnormal muscle was evaluated on 
twenty 3-micrometer paraffin-embedded sections of the diaphragm and gastrocnemius of all study 
groups muscles following previously published methodologies (Chacon-Cabrera et al, 2014) (Fig. 
E2C).  
Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay. In muscle 
paraffin-embedded sections, apoptotic nuclei were identified using the TUNEL assay (Chacon-
Cabrera et al, 2014;Salazar-Degracia et al, 2016).  
Statistical Analysis 
Normality of the study variables was checked using the Shapiro-Wilk test. The mean and the 
standard deviation were used for the descriptive analysis of the numeric variables of interest, 
whereas for the graphical representation of the corresponding variables the parameters mean together 
with the corresponding 95% confidence interval were chosen. Therefore, descriptive analyses of the 
target variables demonstrating the validity and reproducibility of the animal experimental model are 
represented as mean and standard deviation in both Tables 1 and 2 and Fig. 1. The molecular results, 
which are all represented in graphs, are expressed as the mean in each study group together with the 
corresponding 95% confidence interval. In addition, for each variable, analysis of variance 
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(ANOVA) models that included genotype, cancer, and the interaction of both were fitted. All 
hypotheses of interest were tested in the framework of these models: Wild type mice with and 
without cancer-induced cachexia were compared. Whenever, the difference was statistically 
significant, cancer-cachectic and control mice were also compared in both Parp-1-/- and Parp-2-/- 
groups of mice. The corresponding significance levels were adjusted using the Dunnett´s test to 
correct for multiple comparisons. All the statistical analyses were carried out using the statistical 
software R, version 3.3.1 (Vienna, Austria; http://www.r-project.org/). In particular, the contributed 
“Package multcomp” (Hothorn et al, 2008) was used to accomplish the multiple comparisons. 
Statistical significance was set at 0.05. 
The sample size chosen was based on previous studies (Chacon-Cabrera et al, 2014;Chacon-
Cabrera et al, 2015;Fermoselle et al, 2011), where very similar approaches were employed. In 
addition, statistical power was calculated using specific software (StudySize 2.0, CreoStat HB, 
Frolunda, Sweden). Body weight gain was selected as the target variable to estimate the statistical 
power in the study. On the basis of a standard power statistics established at a minimum of 80% and 
assuming an alpha error of 0.05, the former parameter was sufficiently high to detect a minimum 
difference of 1.2 points between groups in the sample size (minimum of N=6/group) and standard 
deviation.  
 
Results 
Validation and reproducibility of the experimental model 
LC-induced cachexia. Figure 1A illustrates the curves of body weight progression in the mice of all 
the experimental groups during the 30-day study period. As shown in Figure 1A and Table 1, at the 
end of the study period (day 30), cachectic wild type mice exhibited a significant reduction in body 
weight gain compared to their respective controls. The weights of diaphragm and gastrocnemius 
muscles and limb strength gain were significantly reduced in cachectic wild type mice (Table 1). 
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Importantly, in Parp-1
-/- 
mice, a statistically significant reduction in these parameters was also 
observed, but to a much lesser extent than that seen in wild type animals (Table 1). In cachectic 
Parp-2
-/- 
mice, no significant differences were observed in body and muscle weights or limb strength 
between cachectic and non-cachectic mice (Table 1).  
The expression of PARP-1 and PARP-2 was confirmed in the subcutaneous tumors of the wild type 
and both groups of knockout mice, as previously reported (Chacon-Cabrera et al, 2015;Mateu-
Jimenez et al, 2016). Compared to cachectic wild type animals, the weights of the subcutaneous 
tumors were reduced in both Parp-1
-/-
 and Parp-2
-/-
 LC-cachectic mice (Table 1). 
Effects of Parp deletion on non-cachectic control animals. As illustrated in Table 1, non-cachectic 
knockout animals (Parp-1
-/-
 and Parp-2
-/-
) exhibited a reduction in the weights of their muscles 
(diaphragm and gastrocnemius) compared to wild type non-tumor animals. In the same transgenic 
mice at the end of the study period, no significant differences were observed in baseline body weight 
or the variables limb muscle strength and body weight gain compared to non-tumor wild type 
animals (Table 1 and Fig. 1A). 
PARP activity in muscles of wild type and Parp-1-/- and Parp-2 -/- mice 
LC-induced cachexia. PARP activity as measured by the number of pADPr-positively stained nuclei 
was significantly increased in both diaphragm and gastrocnemius of cachectic wild type mice 
compared to control animals (Figs. 1B, 1C, E2A, and E2B). No significant differences were seen in 
pADPr-positively stained nuclei counts in the study muscles between cachectic and non-cachectic 
mice among the two groups of knockout animals (Figs. 1B, 1C, E2A and E2B).      
Effects of Parp deletion on non-cachectic control animals. PARP activity was significantly lower in 
diaphragm and gastrocnemius of  both Parp-1
-/- 
and Parp-2
-/- 
control mice than in wild type animals 
(Figs. 1B, 1C, E2A and E2B).             
Deletions of PARP-1 and -2 mitigate increased oxidative stress 
LC-induced cachexia. Total protein carbonylation levels significantly increased in both diaphragm 
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and gastrocnemius muscles of cachectic wild type mice compared to their respective non-cachectic 
controls (Figs. 2A, 2B, E3A, and E3B). Diaphragm and gastrocnemius protein carbonylation levels 
did not differ between cachectic and non-cachectic mice in any group of knockout animals (Figs. 2A, 
2B, E3A, and E3B). Protein levels of SOD2 were significantly lower in both diaphragm and 
gastrocnemius muscles of cachectic wild type mice than in non-tumor control animals (Figs. 2C, 2D, 
E3C, and E3D). No significant differences were found in muscle SOD2 protein levels between 
cachectic and non-cachectic mice in any of the knockout groups (Figs. 2C, 2D, E3C, and E3D). 
Diaphragm or gastrocnemius levels of SOD1 did not significantly differ between cachectic and non-
cachectic mice among the study groups (Figs. 2E, 2F, E3E, and E3F). Among each of the cachectic 
groups of mice, no significant correlations were found between markers of oxidative stress and other 
biological or physiological parameters.  
Effects of Parp deletion on non-cachectic control animals. No significant differences were seen in 
total protein carbonylation, SOD2, or SOD1 levels between non-cachectic knockout mice and the 
non-cachectic wild type animals (Figs. 2A-2F, and E3A-E3F).  
Deletions of PARP-1 and -2 prevent the expression of proteolytic markers in cachectic muscles   
LC-induced cachexia. Protein degradation, as measured by the release of the amino acid tyrosine, 
was significantly increased in both diaphragm and gastrocnemius muscles of cachectic wild type 
mice compared to non-cachectic controls (Figs. 3A and 3B). Parp-1
-/-
 and Parp-2
-/-
 cancer-cachectic 
animals did not show any significant difference in protein degradation levels compared to their 
respective non-cachectic controls in any of the study muscles (Figs. 3A and 3B). Total protein 
ubiquitination and protein content of 20S proteasome subunit C8 were increased in both respiratory 
and limb muscles of cachectic wild type mice compared to non-cachectic controls (Figs. 4A-4D and 
E4A, E4B, E5A, and E5B). The levels of these proteolytic markers did not differ between any of the 
cachectic knockout groups of mice and their respective non-cachectic controls (Figs. 4A-4D and 
E4A, E4B, E5A, and E5B). Protein levels of E3 ligases TRIM32 and MURF-1 did not differ in 
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either respiratory or limb muscles between cachectic and non-cachectic mice of any study group 
(Figs. 5A-5D, and E6A, E6B, E7A, and E7B). However, atrogin-1 content was significantly greater 
in both muscles of cachectic wild type rodents compared to protein levels in non-cachectic controls 
mice, and its levels did not significantly differ in these study muscles between cachectic and non-
cachectic knockout animals (Figs. 5E, 5F, E8A, and E8B). 
Effects of Parp deletion on non-cachectic control animals. Tyrosine release levels were significantly 
greater in the diaphragm and gastrocnemius muscles of non-cachectic Parp-1
-/-
 mice than in wild 
type animals, while no differences were seen between non-tumor Parp-2
-/- 
mice and the wild type 
controls (Figs. 3A and 3B). Total protein ubiquitination, 20S proteasome subunit C8 levels, 
TRIM32, MURF-1 and atrogin-1 levels did not differ in diaphragm or gastrocnemius muscles 
between Parp-1
-/-
 or Parp-2
-/-
 non-cachectic controls and non-cachectic wild type rodents (Figs. 4A-
5F and E4A-E8B).   
Deletions of PARP-1 and -2 attenuate the expression of atrophy signaling pathways in muscles 
LC-induced cachexia. Relative activated NF-kB p50 and NF-kB p65 levels were increased in the 
diaphragm and gastrocnemius muscles of cachectic wild type mice compared to their non-tumor 
controls, whereas no significant differences were observed in the same muscles between any of the 
cachectic knockout mice and their respective non-tumor controls (Figs. 6A-6D, E9A, E9B, E10A, 
and E10B).  
Effects of Parp deletion on non-cachectic control animals. Relative activated NF-kB p50 and p65 
levels did not significantly differ in any muscle between either non-cachectic Parp-1
-/-
 or Parp-2
-/-
 
and the non-cachectic control mice (Figs. 6A-6D, E9A, E9B, E10A, and E10B).  
Deletions of PARP-1 and -2 favor markers of muscle anabolism 
LC-induced cachexia. Compared to their respective non-cachectic controls, cachectic wild type and 
Parp-1
-/-
 animals did not show any significant difference in activated Akt muscle levels in any study 
muscle, while in cachectic Parp-2
-/-
 mice, activated Akt levels were increased in the gastrocnemius 
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but not the diaphragm (Figs. 7A, 7B, E11A, and E11B). In cachectic wild type mice compared to 
wild type controls, activated mTOR levels were significantly reduced in the diaphragm, while an 
almost significant decrease was seen in the gastrocnemius (p=0.096) (Figs. 7C, 7D, E12A, and 
E12B). No significant differences in activated mTOR levels were seen in the diaphragm or 
gastrocnemius muscles between cachectic and non-cachectic mice in any of the knockout groups 
(Figs. 7C, 7D, E12A, and E12B). Compared to non-cachectic controls, no significant differences 
were detected in activated p70S6K levels in the diaphragm of either cachectic wild type or any of the 
knockout mice (Figs. 7E and E13A). Activated p70S6K levels were decreased in the gastrocnemius 
of cachectic wild type mice compared to their non-cachectic controls (Figs. 7F and E13B). Cachectic 
wild type and Parp-2
-/-
 animals showed a significant reduction in mtDNA/nDNA content in both 
respiratory and limb muscles compared to the corresponding non-cachectic controls (Figs. 7G and 
7H, respectively). However, diaphragm or gastrocnemius levels of mtDNA/nDNA did not differ 
between cachectic and non-cachectic conditions in Parp-1
-/-
 mice (Figs. 7G and 7H, respectively).   
Effects of Parp deletion on non-cachectic control animals. No significant differences were seen in 
activated Akt levels between non-cachectic wild type and any of the control knockout groups of mice 
(Figs. 7A-7B, E11A and E11B). Diaphragm levels of mTOR protein did not significantly differ 
between non-cachectic wild type and any of the knockout groups of mice, whereas its levels were 
significantly greater in the gastrocnemius of non-cachectic Parp-2
-/-
 control animals than in wild type 
mice (Figs. 7C-7D, E12A and E12B). P70S6K protein levels and the ratio of mtDNA/nDNA did not 
significantly differ in the study muscles between either non-cachectic Parp-1
-/-
 or Parp-2
-/-
 and the 
non-cachectic wild type mice (Figs. 7E-7H, E13A and E13B).    
Attenuation of muscle atrophy by PARP-1 and -2 deletions 
LC-induced cachexia. The proportions of type I and II fibers did not significantly differ between 
cachectic and non-cachectic conditions in any experimental group of mice (Table 2 and Figs. E14A 
and E14B). The size of both slow- and fast-twitch fibers was significantly reduced in diaphragm and 
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gastrocnemius of cachectic wild type mice compared to the corresponding non-cachectic control 
muscles (Table 2 and Figs. E14A and E14B). However, in both Parp-1
-/-
 and Parp-2
-/-
 mice, the size 
of type I and type II fibers did not significantly differ in the study muscles between cachectic and 
non-cachectic conditions (Table 2 and Figs. E14A and E14B). Proportions of abnormal muscle 
fraction, including inflammatory cell and internal nuclei counts were increased in both respiratory 
and limb muscles in LC-cachectic mice of all experimental groups compared to the corresponding 
non-cachectic controls (Table 2). Compared to the corresponding non-cachectic controls, TUNEL-
stained nuclei counts were increased in respiratory and limb muscles of wild type, Parp-1
-/- 
and Parp-
2
-/-
 cachectic mice (Table 2 and Figs. E15A and E15B).  
Effects of Parp deletion on non-cachectic control animals. Proportions of type I and type II fibers 
did not significantly differ in the study muscles between wild type and either Parp-1
-/- 
or Parp-2
-/-
 
non-cachectic control mice (Table 2 and Figs. E14A and E14B). The size of slow-twitch fibers was 
significantly reduced in the gastrocnemius of non-cachectic Parp-2
-/- 
mice compared to non-cachectic 
wild type animals (Table 2 and Figs. E14A and E14B). Proportions of inflammatory cells were 
almost significantly increased (p=0.055) in the diaphragm of Parp-2
-/-
 controls compared to wild type 
non-cachectic animals (Table 2). Proportions of TUNEL-positively stained nuclei did not 
significantly differ in the study muscles between non-cachectic wild type and any of the knockout 
mice (Table 2 and Figs. E15A and E15B).  
Attenuation of muscle contractile protein loss by PARP-1 and -2 deletions 
LC-induced cachexia. In diaphragm and gastrocnemius of wild type cachectic mice, protein levels of 
contractile MyHC were reduced compared to the non-cachectic controls (Figs. 8A, 8B, E16A, and 
E16B). MyHC protein levels also decreased in the diaphragm but not in the gastrocnemius of 
cachectic Parp-1
-/- 
mice compared to Parp-1
-/- 
non-cachectic control animals (Figs. 8A, 8B, E16A, 
and E16B). MyHC levels did not significantly differ in the study muscles between cachectic and 
non-cachectic Parp-2
-/- 
animals (Figs. 8A, 8B, E16A, and E16B). No significant differences were 
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seen in actin  protein levels in the study muscles between cachectic and non-cachectic conditions in 
any experimental group of mice (Figs. 8C, 8D, E17A, and E17B).  
Effects of Parp deletion on non-cachectic control animals. MyHC and actin levels did not 
significantly differ in the study muscles among any of the non-cachectic control mice (Figs. 8A-8D 
and E16A-E17B).  
 
 
Discussion 
Summary of main study findings 
The main findings in the investigation were that compared to non-cachectic control wild type 
animals, in both diaphragm and gastrocnemius muscles of cancer cachectic wild type mice: 1) PARP 
activity (pADPr levels), protein oxidation, and protein breakdown levels (tyrosine release) were 
increased, 2) levels of markers of the ubiquitin-proteasome system were greater; 3) mitochondrial 
SOD2 and contractile myosin protein contents were decreased, 4) NF-κB signaling pathway was 
activated, and 5) several markers of muscle anabolism were reduced. Specific genetic deletions of 
either Parp-1 or -2 in the cancer cachectic mice attenuated the rise in levels of muscle protein 
oxidation and catabolism, markers of ubiquitin-proteasome system, and NF-κB signaling pathway, 
while causing an improvement in levels of anabolic markers, muscle atrophy and myosin protein 
loss, body and muscle weights, and limb muscle strength. Furthermore, the model of LC-induced 
cachexia has been reproduced and well-validated again in the current investigation. PARP activity 
was demonstrated to be increased in wild type cachectic mice, while it significantly decreased in the 
PARP-1 and -2 deficient mice. We believe that the results encountered in the present study enhance 
existing knowledge in the field of muscle wasting in cancer-induced cachexia. Moreover, deficiency 
of either PARP-1 or -2 induced several beneficial effects on the cachectic animals and their muscles 
that are discussed below.  
Deletion of PARP-1 and -2 activities attenuated increased muscle oxidative stress and 
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proteolysis  
The rise in pADPr levels observed in the muscles of the wild type cancer cachectic mice was a 
major finding in the current study. Furthermore, a significant decrease in pADPr levels was detected 
in both respiratory and limb muscles of Parp-1
-/-
 and Parp-2
-/-
 non-cachectic control mice, confirming 
the validity and reliability of the genetic deletions of both PARP-1 and -2 proteins in the tissues of 
the knockout animals. These findings also suggest that PARP probably plays a relevant role in the 
development of cancer-induced muscle wasting, as the increase in pADPr content was blunted in 
both muscle types of Parp-1
-/-
 and Parp-2
-/-
 cancer-cachectic mice.  
Oxidative stress has been previously demonstrated to trigger muscle mass loss in patients 
(Barreiro et al, 2008;Barreiro et al, 2010b;Fermoselle et al, 2012;Marin-Corral et al, 2010;Puig-
Vilanova et al, 2014) and animal models including the current model of cancer cachexia (Chacon-
Cabrera et al, 2014;Fermoselle et al, 2011;Fermoselle et al, 2012;Puig-Vilanova et al, 2014) and to 
induce the activation of PARP in the nucleus (de et al, 1994;Olah et al, 2015;Ullrich et al, 
1999;Ullrich et al, 2000).  In the present study, protein oxidation levels were greater, while those of 
mitochondrial SOD2 were lower in both muscle types of wild type cancer cachectic mice than in the 
non-cachectic controls. Deletion of PARP-1 and -2 attenuated the rise in protein oxidation and the 
decrease in SOD2 in both respiratory and limb muscles, suggesting that PARP may underlie oxidant 
production and alter antioxidant defense in cancer cachectic muscles. These findings are in line with 
those previously shown in muscle cells, in which resistance to oxidative stress was highly dependent 
on PARP activation (Olah et al, 2015). In fact, it has also been demonstrated that PARP may activate 
proteasomal degradation in response to increased oxidative stress in leukemic cells (Ullrich et al, 
2000). On the basis of those seminal findings, it would be possible to conclude that PARP may have 
also mediated enhanced protein breakdown via the proteasome following oxidative stress in 
respiratory and limb muscles of cancer cachectic mice in the current experimental model. 
Identification of the nature of the oxidized proteins including histones (Ullrich et al, 1999) and other 
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epigenetic changes (Chacon-Cabrera et al, 2015) should be a matter of investigation in future studies.  
Total muscle protein catabolism as measured by the tyrosine release assay was increased in the 
diaphragm and gastrocnemius muscles of the cancer cachectic mice. Genetic inhibition of Parp-1 and 
-2 blunted the rise in protein breakdown in both respiratory and limb muscles of the cancer cachectic 
animals. Interestingly, PARP-1 genetic deletion, but not PARP-2, induced a significant rise in 
tyrosine release levels in both diaphragm and gastrocnemius muscles of the non-cachectic animals 
compared to wild type control mice. These findings are partly in line with those reported by Bai et al 
(Bai et al, 2011b), who showed a rise in energy expenditure together with increased muscle 
mitochondrial metabolism, probably as a result of Sirtuin1 activation, in mice that were genetically 
deficient for PARP-1 enzyme. On the other hand, in a previous study using the same experimental 
model, the decrease in Sirtuin1 induced by cancer cachexia was attenuated in muscles of Parp-1
-/- 
and 
Parp-2
-/-
 cachectic mice (Chacon-Cabrera et al, 2015). Taken together, these findings may imply that 
PARP-1 deletion may lead to a rise in protein catabolism reflected by increased tyrosine release in 
normal muscles. Future research should aim to investigate this pathway in more detail. 
Total protein ubiquitination levels were increased in the cachectic wild type rodents, whereas no 
differences in this proteolytic marker were detected in either Parp-1
-/- 
or Parp-2
-/-
 mice between 
cachectic and non-cachectic conditions. Both PARP-1 and -2 deficiency blunted the rise in protein 
ubiquitination seen in the respiratory and limb muscles of the cachectic knockout mice probably by 
reducing the levels of oxidants, as these were shown to trigger muscle mass loss in animal and 
human studies (Chacon-Cabrera et al, 2014;Puig-Vilanova et al, 2014) and PARP activation induced 
oxidant production (Olah et al, 2015;Ullrich et al, 1999;Ullrich et al, 2000). 
In keeping with, levels of markers of the ubiquitin-proteasome pathway such as the 20S 
proteasome C8 subunit and that of the E3 ligase atrogin-1 were also significantly increased in the 
diaphragm and gastrocnemius muscles of the cachectic wild type rodents compared to the non-tumor 
controls. These findings are in agreement with previous studies, in which markers of this proteolytic 
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system were consistently upregulated in models of muscle wasting (Chacon-Cabrera et al, 
2014;Fermoselle et al, 2011) including patients with cachexia (Fermoselle et al, 2012;Puig-Vilanova 
et al, 2014). Importantly, in both respiratory and limb muscles of Parp-1
-/- 
and Parp-2
-/-
 cachectic 
mice, levels of those two proteolytic markers did not differ from those observed in their respective 
non-cachectic controls. On the other hand, levels of the E3 ligases TRIM-32 and MURF-1 did not 
significantly differ between cachectic and non-cachectic control mice in any of the study muscles. 
Hence, these findings suggest that atrogin-1 is the key muscle-specific ligase involved in 
proteasomal degradation of proteins in the respiratory and limb muscles in this experimental model 
of cachexia.  
In a previous investigation (Chacon-Cabrera et al, 2014), we demonstrated that NF-κB and 
MAPK were the predominant signaling pathways driving muscle mass loss in this experimental 
model of cancer cachexia. Additionally, in the same cachectic wild type mice, transcriptional activity 
of NF-κB was significantly greater in the gastrocnemius muscles than in the non-cachectic control 
mice (Chacon-Cabrera et al, 2014). In agreement with these findings, in the current investigation, 
NF-κB signaling pathway was also activated in the diaphragm and gastrocnemius muscles of the 
cachectic wild type animals. The attenuation in proteolytic degradation seen in the muscles of the 
cachectic knockout animals could be partly the result of decreased NF-κB transcriptional activity 
induced by PARP enzyme deficiency, as was shown to occur in previous studies (Hassa and 
Hottiger, 1999;Oliver et al, 1999). 
 The previously reported decrease in the rate of myofibrilar protein synthesis observed in models 
of cachexia (White JP et al, 2012;White et al, 2011;Toth et al, 2013) and aging (Fry et al, 2011) may 
also partly account for the reduced levels of myosin protein in the cancer cachectic muscles of wild 
type animals seen in the current study. Additionally, reductions in myofibrilar protein content may 
also account for the smaller fiber sizes of slow- and fast-twitch fibers observed in both muscle types 
of the cachectic wild type mice in the investigation. Future studies should be designed in order to 
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specifically explore myofibrilar protein synthesis in cancer-induced cachexia in this animal model 
and whether reduced protein synthesis or enhanced protein catabolism play a predominant role in the 
process of muscle mass loss. In the study, protein levels of MyHC, a major target for proteolysis in 
skeletal muscles, were significantly lower in muscles of the wild type cachectic mice. These findings 
are in line with results previously reported by our group on diaphragm (Marin-Corral et al, 2009) and 
quadriceps muscles of patients with advanced COPD and cancer cachexia (Fermoselle et al, 
2012;Puig-Vilanova et al, 2014), as well as in muscles of mice with emphysema-induced cachexia 
(Fermoselle et al, 2011;Salazar-Degracia et al, 2016). A relevant finding in the investigation was the 
attenuation of the decrease in MyHC protein content observed in the study muscles induced by 
PARP-1 and -2 genetic deletions, especially in the gastrocnemius, of the cachectic animals probably 
through attenuation of both oxidative stress and increased myofibrillar proteolysis. Moreover, the 
attenuation of protein degradation may also account for the improvements observed in body and 
muscle weights and limb muscle strength in Parp-1
-/- 
and Parp-2
-/-
 cachectic mice. On the other hand, 
the study of the potential contribution of PARP activation to muscle protein synthesis in models of 
cachexia also deserves special attention in future studies. 
Genetic deletion of PARP-1 and -2 proteins promoted the expression of anabolic markers  
Levels of mTOR were lower in the diaphragm and gastrocnemius and those of p70SK6 also in 
the latter muscles of the cachectic wild type mice compared to the non-tumor controls. These 
findings are in agreement with those reported in models of colon cancer cachexia in mice (White et 
al, 2011) and in muscles from cancer-cachectic and elderly subjects (Fry CS et al, 2011;Toth et al, 
2013), in which mTOR signaling was suppressed together with a decline in the rate of myofibrilar 
protein synthesis. Importantly, in cachectic Parp-1
-/- 
and Parp-2
-/-
 mice, the decrease in mTOR levels 
was attenuated in both muscles, thus suggesting that PARP-1 and -2 may interact with mTOR 
signaling in this model of muscle wasting, especially in the limb muscle, in which mTOR levels were 
even greater in non-cachectic control Parp-2
-/-
 mice. Indeed, previous studies have shown that 
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pharmacological inhibitors of PARP prevent mTOR downregulation through its role in the 
modulation of adenosine monophosphate-activated protein kinase pathways (Ethier et al, 2012).  
Mitochondrial content as measured by the ratio of mitochondrial to nuclear DNA was reduced 
in diaphragm and gastrocnemius muscles of cachectic wild type animals compared to non-cachectic 
controls. These results are in line with those recently reported in other investigations, in which 
mitochondrial respiratory chain dysfunction (Fermoselle et al, 2013) and mitochondrial content 
impairment was shown to occur early in the initiation of cachexia (White JP et al, 2012) and in 
muscles of rats bearing the Yoshida ascites hepatoma (Fontes-Oliveira et al, 2014;Fontes-Oliveira et 
al, 2013). Interestingly, in cachectic Parp-1
-/-
 and Parp-2
-/-
 mice (only the diaphragm), the reduction 
in mitochondrial content was attenuated in muscles of the cachectic rodents. These findings are in 
line with previous data showing an improvement in mitochondrial content upon inhibition of PARP-
1, probably via Sirtuin1 activity (Bai et al, 2015;Rajamohan et al, 2009). Depletion of PARP-2 also 
resulted in enhanced Sirtuin1 activity and increased mitochondrial content in several in vitro models 
(Bai et al, 2011a;Mohamed et al, 2014). Differences between Parp-1
-/-
 and Parp-2
-/-
 cachectic mice in 
mitochondrial content observed in this study may be the result of the distinctive interaction of PARP-
1 and -2 with Sirtuin1 promoter: while PARP-2 does not modify Sirtuin1 promoter activity, PARP-2 
suppresses its activity (Bai et al, 2011b). These findings warrant special attention in further studies in 
which the specific role of PARP-1 and -2 in mitochondrial remodeling and function should be 
explored. The potential beneficial effects of PARP deletion on mitochondrial respiratory chain 
function and oxidative metabolism (Bai et al, 2011b;Bai et al, 2011a;Bai et al, 2015) should also be a 
matter of research in future investigations focused on the thorough assessment of these organelles in 
models of cancer-induced cachexia (Fontes-Oliveira et al, 2013;Tzika et al, 2013).  
Study limitations  
It is likely that the reduction in tumor burden observed in both groups of knockout mice may have 
partly contributed to favoring body and muscle mass gain in the mice. In fact, deficiency of both 
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PARP-1 and -2 induced a reduction in tumor weights in the animals, as has recently been 
demonstrated through several biological mechanisms (Chacon-Cabrera et al, 2015;Mateu-Jimenez et 
al, 2016). In the current investigation, diaphragmatic contractile function was not measured as the 
main focus was to assess the effects of PARP1- and -2 deletions in the peripheral muscles of the 
target mice. Moreover, such studies would have implied the use of a different approach and a 
significantly greater number of animals for the in vitro contractility studies, which was not allowed 
for ethical reasons in the institution. Indeed, in this investigation, the assessment of the biological 
pathways whereby PARP deletion may attenuate muscle mass loss in cancer-induced cachexia was 
prioritized over other types of experiments.  
Another limitation is related to the lack of measurements on the progression of tumor size 
throughout the study protocol in the tumor-bearing animals. In the study, tumor weights were only 
available at the time of sacrifice in all experimental groups, partly because the investigation focused 
on the assessment of the tumor effects on the actual cachectic muscles. Moreover, the weights of 
organs such as the liver or heart were not available in all the study animals. As no significant 
differences were detected in body weight gain among the non-tumor control groups of animals, and 
an improvement was seen in Parp-1
-/-
 and Parp-2
-/-
 cachectic mice compared to their respective non-
tumor controls, we believe that it is not a major limitation in the study. Indeed, a major strength in 
the investigation was that the potential beneficial effects of PARP-1 and PARP-2 genetic deletions 
have been explored independently in two different groups of knockout mice from the following 
perspectives: the analyses of biological events involved in muscle oxidative stress, catabolism, 
anabolism, and signaling in the context of a reproducible mouse model of cancer-induced cachexia, 
as confirmed by the reduced whole body and muscle weights, and limb strength and the presence of 
muscle atrophy. Future research should focus on the assessment of whether selective 
pharmacological inhibitors of PARP-1 and -2 exert similar beneficial effects on muscles in models of 
cancer cachexia including those in clinical settings, since pharmacological inhibitors of PARP-1 and 
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-2 are currently available for the treatment of certain cancer types. Nonetheless, prior to establishing 
a beneficial effect on muscle mass loss and metabolism of PARP pharmacological inhibition in 
patients with cancer-induced cachexia, the selective role of either PARP-1 or PARP-2 enzymes in 
protein catabolism and anabolism, muscle phenotype and function deserved to be particularly studied 
in an experimental model of cancer-induced cachexia using specific transgenic mice.  
Conclusions 
In respiratory and limb muscles of tumor-bearing mice with cachexia, PARP activity pathway 
underlies enhanced protein catabolism through increased oxidative stress, activation of the ubiquitin-
proteasome system, and NF-kB signaling. The reduction in contractile myosin content and atrophy 
signature of the myofibers was substantially attenuated in respiratory and limb muscles of the 
cachectic Parp-1
-/- 
or Parp-2
-/-
 mice, while no effects were seen in other structural features. Markers 
of muscle anabolism partly improved in both diaphragm and gastrocnemius muscles of the cachectic 
PARP-deficient mice, especially in cachectic Parp-1
-/- 
animals. The expression pattern of the 
biological events observed in the study muscles was similar in Parp-1
-/- 
and Parp-2
-/-
 LC-cachectic 
animals, except for mitochondrial content. Collectively, the study findings imply that activation of 
either PARP-1 or -2 is likely to play a relevant role in muscle protein catabolism via oxidative stress, 
NF-kB signaling and enhanced proteasomal degradation in cancer-induced cachexia. Despite the 
potential limitations of PARP activity inhibition, since it plays a key role in DNA maintenance, 
exploration of its reliability and likely applicability as a possible target for future therapeutic 
interventions deserves attention in models of cancer-induced cachexia.   
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FIGURE LEGENDS 
Fig. 1A Mean values and standard deviations of the progression of the actual body weights in mice 
from all the experimental groups are represented in the graph. Each experimental group is 
represented by the following signs: non-cachectic control wild type animals (light-blue circles, 
N=12), LC-cachectic wild type mice (red squares, N=14), non-cachectic control Parp-1
-/-
 rodents 
(green triangles, N=8), LC-cachectic Parp-1
-/- 
mice (dark-blue squares, N=12), non-cachectic control 
Parp-2
-/- 
rodents (turquois squares, N=6), and LC-cachectic Parp-2
-/-
 animals (orange circles, N=6) 
over the study period (one month). Statistical significance is represented as follows: **, p≤0.01, ***, 
p≤0.001, and n.s., non-significant differences between either wild type, Parp-1
-/-
, or Parp-2
-/-
 LC-
cachectic mice and their respective control (non-tumor) rodents. Statistical analyses were conducted 
using one-way analysis of variance (ANOVA), in which Dunnett’s post hoc analysis was used to 
adjust for multiple comparisons among the study groups.  
Fig. 1B-C Mean values and the corresponding 95% confidence intervals of the percentage of 
positively-stained nuclei for poly-ADP ribosylation (a marker of PARP activity) in the diaphragm 
(panel B) and gastrocnemius (panel C). For statistical analysis purposes, the following animals were 
used in each group: non-cachectic control wild type (N=8), LC-cachectic wild type (N=8), non-
cachectic control Parp-1
-/- 
(N=8), LC-cachectic Parp-1
-/- 
(N=8), non-cachectic control Parp-2
-/- 
(N=6), 
and LC-cachectic Parp-2
-/- 
(N=6). Non-cachectic control groups are represented in white bars, while 
LC-cachectic groups are represented in grey bars. Definition of abbreviations: LC, Lung cancer; 
PARP, poly-ADP ribose polymerase; ADPr, ADP ribosylation. Statistical significance is represented 
as follows: ***, p≤0.001, and n.s., non-significant differences between either wild type, Parp-1
-/-
, or 
Parp-2
-/-
 LC-cachectic mice and the corresponding control (non-tumor) mice; †, p≤0.05, ††, p≤0.01 
and †††, p≤0.001 between any of the non-cachectic control knockout animals and control (non-
tumor) wild type mice.  Comparisons were assessed using ANOVA models that included genotype, 
cancer, and the interaction of both. 
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Fig. 2A-F Mean values and the corresponding 95% confidence intervals of total carbonylated 
proteins (panels A and B), SOD2 (panels C and D), and SOD1 (panels E and F) in the diaphragm and 
gastrocnemius, as measured by optical densities in arbitrary units (OD, a.u.). For statistical analysis 
purposes, the following animals were used in each group: non-cachectic control wild type (N=7), 
LC-cachectic wild type (N=8), non-cachectic control Parp-1
-/- 
(N=7), LC-cachectic Parp-1
-/- 
(N=8), 
non-cachectic control Parp-2
-/- 
(N=3), and LC-cachectic Parp-2
-/- 
(N=5). Non-cachectic control 
groups are represented in white bars, while LC-cachectic groups are represented in grey bars. 
Definition of abbreviations: LC, Lung cancer; PARP, poly-ADP ribose polymerase; SOD, 
superoxide dismutase; OD, optical densities; a.u., arbitrary units. Statistical significance is 
represented as follows: *, p≤0.05, **, p≤0.01, ***, p≤0.001 and n.s., non-significant differences 
between either wild type, Parp-1
-/-
, or Parp-2
-/-
 LC-cachectic mice and the corresponding non-
cachectic control mice. Comparisons were assessed using ANOVA models that included genotype, 
cancer, and the interaction of both. 
Fig. 3A-B Mean values and the corresponding 95% confidence intervals of muscle proteolysis as 
measured using the tyrosine release assay (nmol/mg/2h) in the diaphragm (panel A) and 
gastrocnemius (panel B) muscles of the following experimental groups: non-cachectic control wild 
type (N=10), LC-cachectic wild type (N=10), non-cachectic control Parp-1
-/- 
(N=8), LC-cachectic 
Parp-1
-/- 
(N=12), non-cachectic control Parp-2
-/-
 (N=6), and LC-cachectic Parp-2
-/- 
(N=6). Non-
cachectic control groups are represented in white bars, while LC-cachectic groups are represented in 
grey bars. Statistical significance is represented as follows: *, p≤0.05, and n.s., non-significant 
differences between either wild type, Parp-1
-/-
, or Parp-2
-/-
 LC-cachectic mice and the corresponding 
non-cachectic control rodents, ††, p≤0.01 between any of the non-cachectic control knockout 
animals and control (non-tumor) wild type mice. Comparisons were assessed using ANOVA models 
that included genotype, cancer, and the interaction of both. 
Fig. 4A-D Mean values and the corresponding 95% confidence intervals of total protein 
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ubiquitination levels (panels A and B), and 20S proteasome C8 subunit content (panels C and D) in 
the diaphragm and gastrocnemius, as measured by optical densities in arbitrary units (OD, a.u.). For 
statistical analysis purposes, the following animals were used in each group: non-cachectic control 
wild type (N=7), LC-cachectic wild type (N=8), non-cachectic control Parp-1
-/- 
(N=7), LC-cachectic 
Parp-1
-/- 
(N=8), non-cachectic control Parp-2
-/- 
(N=3), and LC-cachectic Parp-2
-/- 
(N=5). Non-
cachectic control groups are represented in white bars, while LC-cachectic groups are represented in 
grey bars. Definition of abbreviations: LC, Lung cancer; PARP, poly-ADP ribose polymerase; OD, 
optical densities; a.u., arbitrary units. Statistical significance is represented as follows: *, p≤0.05, 
***, p≤0.001, and n.s., non-significant differences between either wild type, Parp-1
-/-
, or Parp-2
-/-
 
LC-cachectic mice and the corresponding non-cachectic control mice. Comparisons were assessed 
using ANOVA models that included genotype, cancer, and the interaction of both. 
Fig. 5A-F Mean values and the corresponding 95% confidence intervals of TRIM32 (panels A and 
B), MURF-1 (panels C and D), and atrogin-1 (panels E and F) protein content in the diaphragm and 
gastrocnemius as measured by optical densities in arbitrary units (OD, a.u.). For statistical analysis 
purposes, the following animals were used in each group: non-cachectic control wild type (N=7), 
LC-cachectic wild type (N=8), non-cachectic control Parp-1
-/- 
(N=7), LC-cachectic Parp-1
-/- 
(N=8), 
non-cachectic control Parp-2
-/- 
(N=3), and LC-cachectic Parp-2
-/- 
(N=5). Non-cachectic control 
groups are represented in white bars, while LC-cachectic groups are represented in grey bars. 
Definition of abbreviations: TRIM32, tripartite motif containing 32; MURF-1, muscle ring finger 
protein 1; LC, Lung cancer; PARP, poly-ADP ribose polymerase; OD, optical densities; a.u., 
arbitrary units. Statistical significance is represented as follows: ***, p≤0.001 and n.s., non-
significant differences between either wild type, Parp-1
-/-
, or Parp-2
-/-
 LC-cachectic mice and their 
respective control (non-tumor) mice. Comparisons were assessed using ANOVA models that 
included genotype, cancer, and the interaction of both. 
Fig. 6A-D Mean values and the corresponding 95% confidence intervals of p-NF-κB p50/NF-κB p50 
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(panels A and B), and p-NF-κB p65/NF-κB p65 ratios (panels C and D) in the diaphragm and 
gastrocnemius, as measured by optical densities in arbitrary units (OD, a.u.). For statistical analysis 
purposes, the following animals were used in each group: non-cachectic control wild type (N=7), 
LC-cachectic wild type (N=8), non-cachectic control Parp-1
-/- 
(N=7), LC-cachectic Parp-1
-/- 
(N=8), 
non-cachectic control Parp-2
-/- 
(N=3), and LC-cachectic Parp-2
-/- 
(N=5). Non-cachectic control 
groups are represented in white bars, while LC-cachectic groups are represented in grey bars. 
Definition of abbreviations: NF-κB p50, nuclear factor-κB p50 subunit; p-NF-κB p50, 
phosphorylated-NF-κB p50; NF-κB p65, nuclear factor-κB p65 subunit; p-NF-κB p65, 
phosphorylated-NF-κB p65; LC, Lung cancer; PARP, poly-ADP ribose polymerase; OD, optical 
densities; a.u., arbitrary units. Statistical significance is represented as follows:  **, p ≤ 0.01, ***, 
p≤0.001, and n.s., non-significant differences between either wild type, Parp-1
-/-
, or Parp-2
-/-
 LC-
cachectic mice and their respective control (non-tumor) mice; †††, p≤0.001 between any of the 
control knockout animals and control (non-tumor) wild type mice. Comparisons were assessed using 
ANOVA models that included genotype, cancer, and the interaction of both. 
Fig. 7A-H Mean values and the corresponding 95% confidence intervals of p-Akt/Akt (panels A and 
B), p-mTOR/mTOR (panels C and D), and p-p70S6K/p70S6K (panels E and F) ratios are depicted in 
the diaphragm and gastrocnemius, as measured by optical densities in arbitrary units (OD, a.u.). For 
statistical analysis purposes, the following animals were used in each group: non-cachectic control 
wild type (N=7), LC-cachectic wild type (N=8), non-cachectic control Parp-1
-/- 
(N=7), LC-cachectic 
Parp-1
-/- 
(N=8), non-cachectic control Parp-2
-/- 
(N=3), and LC-cachectic Parp-2
-/- 
(N=5). Mean values 
and the corresponding 95% confidence intervals of the mitochondrial DNA copy number in the 
diaphragm (panel G) and gastrocnemius (panel H), as measured by the mtDNA/mDNA ratio in 
arbitrary units (a.u.). For statistical analysis purposes, the following animals were used in each 
group: non-cachectic control wild type (N=8), LC-cachectic wild type (N=8), non-cachectic control 
Parp-1
-/- 
(N=8), LC-cachectic Parp-1
-/- 
(N=8), non-cachectic control Parp-2
-/- 
(N=6), and LC-
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cachectic Parp-2
-/- 
(N=6). Non-cachectic control groups are represented in white bars, while LC-
cachectic groups are represented in grey bars. Definition of abbreviations: Akt, RAC-alpha 
serine/threonine-protein kinase; p-Akt, phosphorylated-Akt; mTOR, mammalian target of 
rapamycin; p-mTOR, phosphorylated mTOR; p70S6K, p70 S6 kinase; p-70S6K, phosphorylated 
p70S6K; LC, Lung cancer; PARP, poly-ADP ribose polymerase; OD, optical densities; a.u., arbitrary 
units. Statistical significance is represented as follows: *, p≤0.05, **, p≤0.01, ***, p≤0.001, and n.s., 
non-significant differences between either wild type, Parp-1
-/-
, or Parp-2
-/-
 LC-cachectic mice and the 
corresponding non-cachectic control (non-tumor) mice; †, p≤0.05 between any of the non-cachectic 
control knockout animals and control (non-tumor) wild type mice. Comparisons were assessed using 
ANOVA models that included genotype, cancer, and the interaction of both. 
Fig. 8A-D Mean values and the corresponding 95% confidence intervals of MyHC (panels A anb B) 
and actin (panels C and D) protein content in the diaphragm and gastrocnemius, as measured by 
optical densities in arbitrary units (OD, a.u.). For statistical analysis purposes, the following animals 
were used in each group: non-cachectic control wild type (N=7), LC-cachectic wild type (N=8), non-
cachectic control Parp-1
-/- 
(N=7), LC-cachectic Parp-1
-/- 
(N=8), non-cachectic control Parp-2
-/- 
(N=3), 
and LC-cachectic Parp-2
-/- 
(N=5). Non-cachectic control groups are represented in white bars, while 
LC-cachectic groups are represented in grey bars. Definition of abbreviations: MyHC, Myosin 
Heavy Chain; LC, Lung cancer; PARP, poly-ADP ribose polymerase; OD, optical densities; a.u., 
arbitrary units. Statistical significance is represented as follows: *, p≤0.05, **, p≤0.01, ***, p≤0.001, 
and n.s., non-significant differences between either wild type, Parp-1
-/-
, or Parp-2
-/-
 LC-cachectic 
mice and the corresponding non-cachectic control animals. Comparisons were assessed using 
ANOVA models that included genotype, cancer, and the interaction of both. 
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Table 1. Validation of the experimental model: physiological characteristics of wild type, Parp-1-/-, and Parp-2-/- mice at the end of the study period 
 
 Wild type mice Parp-1
-/- 
mice Parp-2
-/- 
mice 
 Control 
(N=12)  
LC-cachexia  
(N=14) 
Control  
(N=8) 
LC-cachexia  
(N=12) 
Control  
(N=6) 
LC-cachexia  
(N=6) 
Age at baseline (weeks) 10  10, n.s. 10 10, n.s. 10 10, n.s. 
Subcutaneous tumor weight (g)  1.86 (0.6)  1.11 (0.3), **  1.21 (0.35), * 
Body weight at baseline (g) 19.57 (0.85) 19.52 (0.80), n.s. 19.28 (0.78)  18.61 (0.93), n.s. 19.25 (1.06) 19.89 (0.92), n.s. 
Body weight gain (%)  +9.26 (2.63) -5.39 (9.54), *** +6.96 (2.23) +1.55 (3.69), * +4.34 (2.87)  +3.06 (6.81), n.s. 
Diaphragm weight (g) 0.090 (0.01) 0.067 (0.011), *** 0.073 (0.01), †† 0.062 (0.007), * 0.076 (0.012), † 0.086 (0.013), n.s.  
Gastrocnemius weight (g) 0.118 (0.006) 0.080 (0.018), *** 0.105 (0.003), † 0.096 (0.007), * 0.096 (0.012), ††† 0.098 (0.012), n.s. 
Limb strength gain (%)  +9.48 (6.47) -12.50 (10.52), *** +12.86 (8.13) -0.45 (6.08), ** +3.33 (1.99) +2.10 (5.40), n.s. 
 
The description of the variables that demonstrated the reproducibility of the animal model is presented as mean (standard deviation). 
Definition of abbreviations: Parp-1
-/-
 and Parp-2
-/-
, poly-ADP ribose polymerase-1, and -2 knockout mice, LC, lung cancer; N.A., not applicable.   
Statistical significance: *, p≤0.05, **, p≤0.01, ***, p≤0.001, and n.s., non-significant differences between either wild type, Parp-1
-/-
, or Parp-2
-/-
 LC-
cachectic mice and their respective control (non-tumor) rodents; †, p≤0.05, ††, p≤0.01, and †††, p≤0.001 between any of the control knockout animals and 
control (non-tumor) wild type mice. Comparisons were assessed using one-way analysis of variance (ANOVA), in which Dunnett’s post hoc analysis was 
used to adjust for multiple comparisons among the study groups. 
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Table 2. Muscle phenotypic features in wild type, Parp-1
-/-
, and Parp-2
-/-
 mice at the end of the study period 
 
                                             Wild type mice                                                               Parp-1-/- mice Parp-2-/- mice 
                                       Muscle                 Control                  LC-cachexia  
                                                                    (N=10)                      (N=10) 
Control  
(N=8) 
LC-cachexia  
(N=12) 
Control  
(N=6) 
LC-cachexia 
(N=6) 
Fiber type composition 
Type I fibers (%) 
Diaphragm 9 (2) 8 (3), n.s. 9 (1) 9 (2), n.s. 7 (2) 9 (2), n.s. 
Gastrocnemius 13 (3) 13 (3), n.s. 13 (2) 13 (2), n.s. 17 (4) 15 (2), n.s. 
Type II fibers 
(%) 
Diaphragm 91 (2) 92 (3), n.s. 91 (1) 91 (2), n.s. 92 (3) 90 (2), n.s. 
Gastrocnemius 87 (3) 87 (3), n.s. 87 (2) 87 (2), n.s. 83 (4) 85 (2), n.s. 
Type I fibers area 
(µm
2
) 
Diaphragm 322 (70) 239 (28), ** 325 (77) 289 (58), n.s. 292 (49) 311 (67), n.s. 
Gastrocnemius 965 (107) 673 (121), *** 864 (109) 730 (190), n.s. 775 (128), †  707 (82), n.s. 
Type II fibers 
area (µm
2
) 
Diaphragm 397 (78) 310 (58), * 384 (80) 371 (76), n.s. 344 (98) 395 (114), n.s. 
Gastrocnemius 924 (134) 714 (135), ** 885 (99) 743 (182), n.s. 804 (66) 714 (61), n.s. 
Muscle abnormalities 
Abnormal 
fraction (%) 
Diaphragm 8.8 (0.7) 14.3 (3.9), ** 9.7 (2.3) 16.1 (4.9), *** 11.5 (2.6) 16 (2.5), * 
Gastrocnemius 3.7 (1.6) 7.9 (1.7), *** 4.4 (1) 7.4 (2.1), ** 5.0 (1.8) 8.0 (2.4), * 
Inflammatory 
cells (%) 
Diaphragm 3.9 (0.4) 6.3 (1.4), ** 6 (1.2), p=0.055 9.7 (2.6), *** 6.6 (1.5), †† 9.7 (0.8), ** 
Gastrocnemius 2.1 (1.0) 5.3 (1.8), *** 2.6 (0.6) 4.4 (1.6), * 2.3 (1.1) 4.6 (1.8), * 
Internal nuclei 
(%) 
Diaphragm 3.7 (1.0) 7.2 (3.7), ** 3.3 (1.5) 5.5 (2.2), * 4.3 (0.7) 5.4 (0.6), * 
Gastrocnemius 1.5 (0.7) 2.3 (0.8), * 1.7 (0.8) 2.8 (0.8), ** 2.2 (0.5) 2.8 (0.4), * 
TUNEL – 
positive nuclei 
(%) 
Diaphragm 48.5 (6.7) 65.8 (5.9), *** 49.1 (2.5) 57.5 (1.8), *** 49 (1.8) 59.5 (1.7), *** 
Gastrocnemius 51.6 (5.7) 67.7 (3.8), *** 49 (0.7) 59.5 (2.6), *** 48.6 (1.7) 60.8 (2.4), *** 
 
The description of the variables that demonstrated the reproducibility of the animal model is presented as mean (standard deviation). 
Definition of abbreviations: Parp-1
-/- 
and Parp-2
-/-
, poly-ADP ribose polymerase-1, and -2 knockout mice; LC, lung cancer; µm, micrometer; n.s., 
non-significant.   
Statistical significance: *, p≤0.05, **, p≤0.01, ***, p≤0.001, and n.s., non-significant differences between either wild type, Parp-1
-/-
 or Parp-2
-/-
 LC-
cachectic mice and their respective control (non-tumor) rodents; †, p≤0.05, and ††, p≤0.01 between any of the control knockout animals and control 
(non-tumor) wild type mice. Comparisons were assessed using one-way analysis of variance (ANOVA), in which Dunnett’s post hoc analysis was 
used to adjust for multiple comparisons among the study groups. 
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Figure 5A-5D  
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Figure 6A-6D  
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Figure 7A-7D  
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Figure 7E-7H  
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Figure 8A-8D  
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